Neoplasms Clinical Trials

123 recruiting

Neoplasms Trials at a Glance

815 actively recruiting trials for neoplasms are listed on ClinicalTrialsFinder across 6 cities in 68 countries. The largest study group is Not Applicable with 231 trials, with the heaviest enrollment activity in Houston, Madrid, and Barcelona. Lead sponsors running neoplasms studies include National Cancer Institute (NCI), Janssen Research & Development, LLC, and GlaxoSmithKline.

Treatments under study

About Neoplasms Clinical Trials

Looking for clinical trials for Neoplasms? There are currently 123 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 815 trials

Recruiting
Phase 3

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Ovarian CancerOvarian Neoplasms
Merck Sharp & Dohme LLC900 enrolled28 locationsNCT07318558
Recruiting
Not Applicable

Questionnaire on Congenital Cancer Signs Through Self-Assessment

Pediatric CancerHereditary Cancer SyndromesCancer Predisposition Syndromes+1 more
Insel Gruppe AG, University Hospital Bern205 enrolled1 locationNCT07378423
Recruiting

Epidemiological and Molecular Colorectal Cancer Registry

Colorectal Neoplasms
Hospital Italiano de Buenos Aires2,100 enrolled1 locationNCT02781337
Recruiting
Phase 1

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

Solid TumorsNeoplasms
National Cancer Institute (NCI)65 enrolled1 locationNCT03366116
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 3

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled174 locationsNCT07060807
Recruiting

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NeoplasmsHealthy VolunteersHematologic Neoplasms
National Heart, Lung, and Blood Institute (NHLBI)6,000 enrolled1 locationNCT00071045
Recruiting

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NeoplasmsLi-Fraumeni SyndromeTp53 Mutations
National Cancer Institute (NCI)5,000 enrolled2 locationsNCT01443468
Recruiting
Phase 3

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Breast Neoplasms
BioNTech SE558 enrolled83 locationsNCT07173751
Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Bladder CancerKidney CancerRenal Cancer+2 more
National Cancer Institute (NCI)5,950 enrolled1 locationNCT00026884
Recruiting
Phase 1Phase 2

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled44 locationsNCT06445972
Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Myelofibrosis (MF)Polycythemia Vera (PV)Myeloproliferative Neoplasms (MPNs)
Prelude Therapeutics100 enrolled1 locationNCT07469891
Recruiting

PREgnancy and FERtility Registry

Breast NeoplasmsPregnancyFertility Preservation
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy1,000 enrolled23 locationsNCT02895165
Recruiting
Phase 1Phase 2

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

Prostate CancerProstatic Neoplasms
National Cancer Institute (NCI)300 enrolled1 locationNCT01834001
Recruiting
Phase 2Phase 3

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Endocrine TumorsNeuroblastomaThyroid Neoplasms+2 more
National Cancer Institute (NCI)2,415 enrolled1 locationNCT01005654
Recruiting

Biospecimen Procurement for Head and Neck Disorders

Head and Neck NeoplasmsLaryngeal DiseaseHearing Disorder+2 more
National Cancer Institute (NCI)1,000 enrolled9 locationsNCT03429036
Recruiting
Phase 2

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Prostate CancerProstate AdenocarcinomaProstatic Neoplasms
National Cancer Institute (NCI)42 enrolled1 locationNCT05616650
Recruiting
Not Applicable

Danish Vulva Cancer Recurrence Study

SurvivorshipCirculating Tumor DNAVulvar Cancer+6 more
University of Aarhus1,295 enrolled2 locationsNCT06495554